Published in Atherosclerosis on February 16, 2012
Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease | NCT04826354
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol (2013) 2.60
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses (2013) 1.12
Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag (2012) 0.99
Cholesterol trials and mortality. Br J Clin Pharmacol (2016) 0.92
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc Disord (2014) 0.88
Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients. Atherosclerosis (2012) 0.85
Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis (2013) 0.84
Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Am J Cardiol (2012) 0.83
Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats. Lipids Health Dis (2014) 0.81
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy. Curr Cardiol Rep (2013) 0.76
Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition. PLoS One (2015) 0.76
Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. Lipids Health Dis (2015) 0.76
Effects of Statin versus the Combination of Ezetimibe plus Statin on Serum Lipid Absorption Markers in Patients with Acute Coronary Syndrome. J Lipids (2015) 0.76
Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux. J Lipid Res (2016) 0.76
Ezetimibe in combination with a statin does not reduce all-cause mortality. J Clin Med Res (2013) 0.75
Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease. J Am Heart Assoc (2015) 0.75
Influence of atherosclerosis-related risk factors on serum high-sensitivity C-reactive protein levels in patients with type 2 diabetes: Comparison of their influence in obese and non-obese patients. J Diabetes Investig (2015) 0.75
Stabilization of high-risk plaques. Cardiovasc Diagn Ther (2016) 0.75
Glycaemic Effects of Non-statin Lipid-Lowering Therapies. Curr Cardiol Rep (2016) 0.75
Ezetimibe: an update on its clinical usefulness in specific patient groups. Ther Adv Chronic Dis (2016) 0.75
[Severe hypertriglyceridemia : Diagnostics and new treatment principles]. Internist (Berl) (2017) 0.75
Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis (2017) 0.75
Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med (2007) 25.17
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med (2010) 4.87
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2010) 4.56
ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2012) 4.45
The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med (2004) 3.78
Off-pump vs conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and quality-of-life outcomes: a randomized trial. JAMA (2004) 3.48
Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J (2005) 3.26
Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation. Cell Metab (2013) 3.00
Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! J Am Coll Cardiol (2012) 2.93
Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol (2010) 2.86
Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA (2003) 2.60
Predictors of long-term survival after coronary artery bypass grafting surgery: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database (the ASCERT study). Circulation (2012) 2.54
Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation (2008) 2.53
Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA (2013) 2.53
Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol (2010) 2.49
Outcomes and long-term survival for patients undergoing mitral valve repair versus replacement: effect of age and concomitant coronary artery bypass grafting. Circulation (2003) 2.45
Long-term follow-up of coronary artery disease presenting in young adults. J Am Coll Cardiol (2003) 2.30
Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients. JAMA (2011) 2.29
Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol (2013) 2.15
Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation (2011) 2.08
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc (2006) 2.07
Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int (2003) 2.04
Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease. Atherosclerosis (2005) 2.02
Obesity during childhood and adolescence augments bone mass and bone dimensions. Am J Clin Nutr (2004) 2.00
Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol (2006) 1.98
Understanding the pathophysiology of apical ballooning syndrome: a step closer. Expert Rev Cardiovasc Ther (2014) 1.97
Causes of death in sickle cell disease: an autopsy study. Br J Haematol (2003) 1.96
Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). J Am Coll Cardiol (2013) 1.86
Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. Circulation (2002) 1.85
Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. Am Heart J (2012) 1.84
Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation (2009) 1.82
Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol (2005) 1.75
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol (2009) 1.75
Neuropsychological outcome after percutaneous coronary intervention or coronary artery bypass grafting: results from the Stent or Surgery (SoS) Trial. Circulation (2004) 1.73
Coronary stent restenosis in patients treated with cilostazol. Circulation (2005) 1.73
Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin (2011) 1.66
Diagnosing and managing cutaneous pigmented lesions: primary care physicians versus dermatologists. J Gen Intern Med (2006) 1.65
Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation (2004) 1.63
The relationship between plasma levels of oxidized and reduced thiols and early atherosclerosis in healthy adults. J Am Coll Cardiol (2006) 1.59
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol (2011) 1.58
Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol (2011) 1.58
The relationship between B-type natriuretic peptide and health status in patients with heart failure. J Card Fail (2005) 1.58
Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial. Circ Cardiovasc Interv (2011) 1.56
Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther (2003) 1.55
A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol (2002) 1.54
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin (2006) 1.53
Predicting cardiovascular events with coronary calcium scoring. N Engl J Med (2008) 1.53
Economic analysis of a transesophageal echocardiography-guided approach to cardioversion of patients with atrial fibrillation: the ACUTE economic data at eight weeks. J Am Coll Cardiol (2004) 1.52
Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy. South Med J (2009) 1.51
The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Am J Cardiol (2006) 1.47
Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary intervention. J Interv Cardiol (2009) 1.47
Depressive symptoms after acute myocardial infarction: evidence for highest rates in younger women. Arch Intern Med (2006) 1.47
Relationship between procedure indications and outcomes of percutaneous coronary interventions by American College of Cardiology/American Heart Association Task Force Guidelines. Circulation (2005) 1.47
Risk of local adverse events following cardiac catheterization by hemostasis device use and gender. J Invasive Cardiol (2004) 1.47
Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol (2003) 1.47
Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). Am J Cardiol (2010) 1.46
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol (2011) 1.45
Economic outcome of cardiac CT-based evaluation and standard of care for suspected acute coronary syndrome in the emergency department: a decision analytic model. Acad Radiol (2011) 1.45
Long-term follow-up of polytetrafluoroethylene-covered stents implanted during percutaneous coronary intervention for management of acute coronary perforation. Catheter Cardiovasc Interv (2011) 1.44
Prognostic implication of creatine kinase release after elective percutaneous coronary intervention in the pre-IIb/IIIa antagonist era. Am Heart J (2003) 1.44
Many Americans have pre-diabetes and should be considered for metformin therapy. Diabetes Care (2009) 1.43
Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol (2011) 1.43
Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial. Circ Cardiovasc Qual Outcomes (2009) 1.43
Linking the National Cardiovascular Data Registry CathPCI Registry with Medicare claims data: validation of a longitudinal cohort of elderly patients undergoing cardiac catheterization. Circ Cardiovasc Qual Outcomes (2012) 1.42
A longitudinal assessment of coronary interventional program quality: a report from the American College of Cardiology-National Cardiovascular Data Registry. JACC Cardiovasc Interv (2009) 1.41
Cardiovascular risk factors one year after a hypertensive disorder of pregnancy. J Womens Health (Larchmt) (2014) 1.40
The importance of cardiorespiratory fitness in the United States: the need for a national registry: a policy statement from the American Heart Association. Circulation (2013) 1.37
Development of a risk adjustment mortality model using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) experience: 1998-2000. J Am Coll Cardiol (2002) 1.35
Report of the National Heart, Lung, and Blood Institute working group on outcomes research in cardiovascular disease. Circulation (2005) 1.34
The American Heart Association's principles for comparative effectiveness research: a policy statement from the American Heart Association. Circulation (2009) 1.33
Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol (2013) 1.31
Time course of depression and outcome of myocardial infarction. Arch Intern Med (2006) 1.30
Random plasma glucose in serendipitous screening for glucose intolerance: screening for impaired glucose tolerance study 2. J Gen Intern Med (2008) 1.28
Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure. Am Heart J (2005) 1.27
Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther (2008) 1.24
Utility estimates for decision-analytic modeling in chronic heart failure--health states based on New York Heart Association classes and number of rehospitalizations. Value Health (2008) 1.24
Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments. Circulation (2007) 1.24
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol (2011) 1.22
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Excessive daytime sleepiness is associated with poor medication adherence in adults with heart failure. J Card Fail (2010) 1.19
ACCF/AHA 2011 key data elements and definitions of a base cardiovascular vocabulary for electronic health records: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards. J Am Coll Cardiol (2011) 1.19
Effect of a psychoeducational intervention on depression, anxiety, and health resource use in implantable cardioverter defibrillator patients. Pacing Clin Electrophysiol (2009) 1.18
Development of 2 registry-based risk models suitable for characterizing hospital performance on 30-day all-cause mortality rates among patients undergoing percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes (2012) 1.17
Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial. J Am Coll Cardiol (2009) 1.15
Endothelial function and aminothiol biomarkers of oxidative stress in healthy adults. Hypertension (2008) 1.15
Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss). Eur J Dermatol (2008) 1.15
Multicenter experience in revascularization of very elderly patients. Am Heart J (2004) 1.15